Insider Selling: FibroGen, Inc (NASDAQ:FGEN) Director Sells 2,000 Shares of Stock

FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $52.24, for a total transaction of $104,480.00. Following the completion of the sale, the director now directly owns 26,000 shares in the company, valued at $1,358,240. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kalevi Kurkijarvi also recently made the following trade(s):

  • On Thursday, August 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $40.74, for a total transaction of $81,480.00.
  • On Monday, September 18th, Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock. The stock was sold at an average price of $46.65, for a total transaction of $186,600.00.

FibroGen, Inc (NASDAQ FGEN) traded up 3.14% during midday trading on Friday, reaching $55.90. 495,089 shares of the company traded hands. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $60.15. The firm’s market capitalization is $3.98 billion. The company’s 50-day moving average price is $53.48 and its 200 day moving average price is $38.02.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The company had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. On average, equities analysts anticipate that FibroGen, Inc will post ($1.81) earnings per share for the current year.

WARNING: “Insider Selling: FibroGen, Inc (NASDAQ:FGEN) Director Sells 2,000 Shares of Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/10/27/insider-selling-fibrogen-inc-fgen-director-sells-2000-shares-of-stock.html.

FGEN has been the topic of a number of recent analyst reports. Jefferies Group LLC began coverage on shares of FibroGen in a research report on Monday, July 10th. They set a “buy” rating and a $50.00 price objective for the company. Goldman Sachs Group, Inc. (The) cut shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research report on Friday, July 21st. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Stifel Nicolaus increased their target price on shares of FibroGen from $38.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, Citigroup Inc. increased their target price on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. FibroGen has a consensus rating of “Buy” and a consensus price target of $65.67.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in FibroGen by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after purchasing an additional 761,421 shares during the last quarter. BlackRock Inc. raised its position in FibroGen by 12.3% in the 2nd quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock valued at $161,545,000 after purchasing an additional 546,587 shares during the last quarter. FMR LLC raised its position in FibroGen by 96.9% in the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after purchasing an additional 1,641,423 shares during the last quarter. State Street Corp raised its position in FibroGen by 16.4% in the 2nd quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock valued at $56,962,000 after purchasing an additional 248,922 shares during the last quarter. Finally, Hillhouse Capital Management Ltd. raised its position in FibroGen by 75.0% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $56,525,000 after purchasing an additional 750,000 shares during the last quarter. Hedge funds and other institutional investors own 47.37% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply